Philip Coffino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philip Coffino has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Sanford M. Simon
Laboratory of Cellular Biophysics, The Rockefeller University, New York, NY 10065, USA
17 shared publications - Barbara Lyons
Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003
15 shared publications - David Requena
Laboratory of Cellular Biophysics, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA
14 shared publications - Henrik Molina
Proteomics Resource Center, The Rockefeller University, New York, NY 10065
14 shared publications - Mahsa Shirani
Laboratory of Cellular Biophysics, The Rockefeller University; NY, NY 10065
14 shared publications - Solomon Levin
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA
14 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
The Spatial transcriptomics data from figure 7 with the cell by cell data for the transcripts of Cyp3A, Muc13 and Col11A1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
The Spatial transcriptomics data from figure 7 with the cell by cell data for the transcripts of Cyp3A, Muc13 and Col11A1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 1 Levels of PKA subunits between FLC and adjacent normal tissue as assessed by mass spectrometry (peptides) or transcriptome. With trypsin digestion a unique peptide was not detected at the fusion junction between DNAJB1 and PRKACA
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 1 Levels of PKA subunits between FLC and adjacent normal tissue as assessed by mass spectrometry (peptides) or transcriptome. With trypsin digestion a unique peptide was not detected at the fusion junction between DNAJB1 and PRKACA
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 2: EC50 (µm) of the drugs tested on cells dissociated from patients tumors expressing (middle column) DNAJB1::PRKACA or (right column) ATP1B1::PRKACA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 2: EC50 (µm) of the drugs tested on cells dissociated from patients tumors expressing (middle column) DNAJB1::PRKACA or (right column) ATP1B1::PRKACA.
- Open Access
Specific degrader for fusion oncokinase kills tumors and is augmented by bimodal degrader-siRNA
Oncogenic fusions of two native proteins are challenging to block without disturbing the parental proteins. A mRNA delivered peptide degrader, selectively eliminates the oncogenic fusions DNAJB1::PRKACA and ATP1B1::PRKACA in fibrolamellar carcinoma (FLC), cholangiocarcinoma and intraductal pancreatic neoplasm, without effect on native PRKACA. Specific degradation reflected structural properties of the fusion proteins. The degrader was lethal to FLC tumor cells in a preclinical model, with no effect on non-FLC cells. To enhance efficacy and speed, we modified the mRNA to simultaneously encode the degrader and an siRNA against the fusion transcript, reducing new protein synthesis which accelerated degradation of DNAJB1::PRKACA, offering a wide therapeutic index for mutation-driven disease.
Open AccessSpecific degrader for fusion oncokinase kills tumors and is augmented by bimodal degrader-siRNA
Oncogenic fusions of two native proteins are challenging to block without disturbing the parental proteins. A mRNA delivered peptide degrader, selectively eliminates the oncogenic fusions DNAJB1::PRKACA and ATP1B1::PRKACA in fibrolamellar carcinoma (FLC), cholangiocarcinoma and intraductal pancreatic neoplasm, without effect on native PRKACA. Specific degradation reflected structural properties of the fusion proteins. The degrader was lethal to FLC tumor cells in a preclinical model, with no effect on non-FLC cells. To enhance efficacy and speed, we modified the mRNA to simultaneously encode the degrader and an siRNA against the fusion transcript, reducing new protein synthesis which accelerated degradation of DNAJB1::PRKACA, offering a wide therapeutic index for mutation-driven disease.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 2: EC50 (µm) of the drugs tested on cells dissociated from patients tumors expressing (middle column) DNAJB1::PRKACA or (right column) ATP1B1::PRKACA.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 2: EC50 (µm) of the drugs tested on cells dissociated from patients tumors expressing (middle column) DNAJB1::PRKACA or (right column) ATP1B1::PRKACA.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
The Spatial transcriptomics data from figure 7 with the cell by cell data for the transcripts of Cyp3A, Muc13 and Col11A1
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
The Spatial transcriptomics data from figure 7 with the cell by cell data for the transcripts of Cyp3A, Muc13 and Col11A1
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 2: EC50 (µm) of the drugs tested on cells dissociated from patients tumors expressing (middle column) DNAJB1::PRKACA or (right column) ATP1B1::PRKACA.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 2: EC50 (µm) of the drugs tested on cells dissociated from patients tumors expressing (middle column) DNAJB1::PRKACA or (right column) ATP1B1::PRKACA.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 1 Levels of PKA subunits between FLC and adjacent normal tissue as assessed by mass spectrometry (peptides) or transcriptome. With trypsin digestion a unique peptide was not detected at the fusion junction between DNAJB1 and PRKACA
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 1 Levels of PKA subunits between FLC and adjacent normal tissue as assessed by mass spectrometry (peptides) or transcriptome. With trypsin digestion a unique peptide was not detected at the fusion junction between DNAJB1 and PRKACA
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 1 Levels of PKA subunits between FLC and adjacent normal tissue as assessed by mass spectrometry (peptides) or transcriptome. With trypsin digestion a unique peptide was not detected at the fusion junction between DNAJB1 and PRKACA
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Supplemental Table 1 Levels of PKA subunits between FLC and adjacent normal tissue as assessed by mass spectrometry (peptides) or transcriptome. With trypsin digestion a unique peptide was not detected at the fusion junction between DNAJB1 and PRKACA
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Fibrolamellar hepatocellular carcinoma (FLC) is a rare liver cancer that is driven by the fusion of DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). PKA activity is controlled through regulatory proteins that both inhibit catalytic activity and control localization, and an excess of regulatory subunits ensures PRKACA activity is inhibited. Here, we found an increase in the ratio of catalytic to regulatory units in FLC patient tumors driven by DNAJB1::PRKACA using mass spectrometry, biochemistry, and immunofluorescence, with increased nuclear localization of the kinase. Overexpression of DNAJB1::PRKACA, ATP1B1::PRKACA, or PRKACA, but not catalytically inactive kinase, caused similar transcriptomic changes in primary human hepatocytes, recapitulating the changes observed in FLC. Consistently, tumors in patients missing a regulatory subunit or harboring an ATP1B1::PRKACA fusion were indistinguishable from FLC based on the histopathological, transcriptomic, and drug–response profiles. Together, these findings indicate that the DNAJB1 domain of DNAJB1::PRKACA is not required for FLC. Instead, changes in PKA activity and localization determine the FLC phenotype.Significance: Alterations leading to unconstrained protein kinase A signaling, regardless of the presence or absence of PRKACA fusions, drive the phenotypes of fibrolamellar hepatocellular carcinoma, reshaping understanding of the pathogenesis of this rare liver cancer.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Fibrolamellar hepatocellular carcinoma (FLC) is a rare liver cancer that is driven by the fusion of DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). PKA activity is controlled through regulatory proteins that both inhibit catalytic activity and control localization, and an excess of regulatory subunits ensures PRKACA activity is inhibited. Here, we found an increase in the ratio of catalytic to regulatory units in FLC patient tumors driven by DNAJB1::PRKACA using mass spectrometry, biochemistry, and immunofluorescence, with increased nuclear localization of the kinase. Overexpression of DNAJB1::PRKACA, ATP1B1::PRKACA, or PRKACA, but not catalytically inactive kinase, caused similar transcriptomic changes in primary human hepatocytes, recapitulating the changes observed in FLC. Consistently, tumors in patients missing a regulatory subunit or harboring an ATP1B1::PRKACA fusion were indistinguishable from FLC based on the histopathological, transcriptomic, and drug–response profiles. Together, these findings indicate that the DNAJB1 domain of DNAJB1::PRKACA is not required for FLC. Instead, changes in PKA activity and localization determine the FLC phenotype.Significance: Alterations leading to unconstrained protein kinase A signaling, regardless of the presence or absence of PRKACA fusions, drive the phenotypes of fibrolamellar hepatocellular carcinoma, reshaping understanding of the pathogenesis of this rare liver cancer.